“In the study, published Wednesday in the New England Journal of Medicine and conducted by researchers in the U.S., U.K., Denmark, France. Italy and Germany, patients received doses of semaglutide, the active ingredient used to treat diabetes in Ozempic and obesity in Wegovy.

The patients started on low doses and increased gradually, reaching the full Wegovy dose over 72 weeks. Researchers found that about two-thirds of patients had less liver inflammation, and about one-third had improvement in liver scarring, a more advanced stage of damage. Additionally, one-third of patients improved in both inflammation and scarring.

These benefits appeared in people with and without diabetes. Patients also lost an average of 8.5% of their body weight during the 72-week study.”

From ABC News.